Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Oncology

LEQEMBI Intravenous Infusion Approval; Novartis...

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and...

Sep 26, 2023

Pharma News for Almirall, GSK, Cellectar
FDA Approves Ojjaara for Myelofibrosis; EMA Grants PRIME Designation to Iopofosine I-131; EBGLYSS Receives Positive CHMP Opinion; FDA Accepts Resmetirom NDA; FDA Fast Track Designation to KT-333 for PTCL; RedHill Announces FDA sNDA Approval for Talicia®

EBGLYSS Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis Almirall S.A. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment o...

Find More
myelodysplastic-syndrome-treatment
Myelodysplastic Syndrome Treatment Market: Unveiling the Robust Pipeline

The number of people diagnosed with myelodysplastic syndrome in the US each year is unknown. However, some estimates have put this number at about 10,000, while other estimates have been much higher. Moreover, myelodysplastic syndrome is uncommon before age 50, and the risk increases as a person gets older. It is a...

Find More
Pharma News for BMS, Alnylam, MaaT Pharma
BMS’s LPA1 Antagonist; Alnylam’s KARDIA-1 Phase 2 Study; Day One Biopharma Sought FDA Approval for Tovorafenib; EMA Orphan Drug Designation to MaaT Pharma’s MaaT033; Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole + Sertraline; Phase III CheckMate – 227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase II Study BMS-986278, a potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, was studied in patients with progressive pulmonary fibrosis (PPF)...

Find More

More Views & Analysis

bms-and-janssen-multiple-myeloma-treatment-drugs-landscape
BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refrac...

Find More

antibody-drug-conjugates-adcs-in-lung-cancer-treatment
A Quick Review of Antibody-Drug Conjugates (ADCs) in Lung Cancer: HER2, TROP-2, HER3, MET, and CEACAM5 ADC Advancements

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Find More

Pain Management Devices Market
Revolutionizing Pain Management: The Growth in Innovative Devices and Rise of Market

Chronic pain is an unwelcome companion in the journey of life and can significantly impact the quality of life. Being in pain serves as a protective mechanism that warns us when something is wrong with the concerned body part, and is a natural component of the human experience. But for millions of people around the...

Find More

Pharma News for Faron, Roche, Ergomed, Menarini
Daiichi Sankyo’s Trastuzumab Deruxtecan; ODD to Bexmarilimab for AML; Roche’ Alecensa; Ergomed Aims To Go Private; Tagraxofusp Receives ODD in Japan for BPCDN; FDA Fast Track Designation to Abliva’s KL1333

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...

Find More

cd38-directed-therapies-for-multiple-myeloma-treatment
Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

The landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...

Find More

MedTech News for GE, Medtronic; Epineuron
GE HealthCare Launched CardioVisio; J&J’s Elita Laser Correction Platform; ICU Medical’s Plum Duo Infusion Pump and LifeShield Infusion Safety Software Update; Medtronic’s Inceptiv SCS with Closed-Loop Sensing to Treat Chronic Pain; Boston Scientific’s FARAPULSE Pulsed Field Ablation System; Epineuron’s REGAIN Trial

GE HealthCare Launched CardioVisio for Atrial Fibrillation, a Digital, Patient-Centric Clinical Decision Support Tool to Enable Precision Care On August 24, 2023, GE HealthCare launched CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relev...

Find More

COVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can.....

Find More

Halitosis is an oral health problem caused by volatile molecules which are formed because of patholo.....

Find More

With its innovative approach, chimeric antigen receptor T cell therapy created a new dawn in the age.....

Find More

The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....

Find More

Postoperative Pain is the pain that an individual experiences after a major operation or surgical pr.....

Find More

BK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....

Find More